Controversies regarding hormone therapy: Insights from inflammation and hemostasis

Cardiovascular Research

Volumn 70, Issue 1, 2006, Pages 22-30

  Koh, Kwang Kon ^a   Yoon, Byung Koo ^b  

^a Gachon University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Hemostasis; Hormone therapy; Inflammation; Lower doses; Tibolone

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CONJUGATED ESTROGEN; CYTOKINE; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; MEDROXYPROGESTERONE ACETATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIBOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGING; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ESTROGEN THERAPY; FIBRINOLYSIS; HEART PROTECTION; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; ISCHEMIC HEART DISEASE; OBESITY; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION;

ADULT; ANDROGEN ANTAGONISTS; ANIMALS; BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; RISK;

EID: 33645084778     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.12.004     Document Type: Review

References (82)

1. K.K. Koh Effects of estrogen on the vascular wall: vasomotor function and inflammation Cardiovasc Res 55 2002 714 726
2. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
3. K.K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res 47 2000 648 657
4. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
5. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, and B. Riggs Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
6. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. The Women's Health Initiative steering committee JAMA 291 2004 1701 1712
7. F. Grodstein, J.E. Manson, and M.J. Stampfer Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study Ann Intern Med 135 2001 1 8
8. K.K. Koh, M.K. Horne III, and R.O. Cannon III Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women Thromb Haemost 82 1999 626 633
9. M. Visser, L.M. Bouter, G.M. McQuillan, M.H. Wener, and T.B. Harris Elevated C-reactive protein levels in overweight and obese adults JAMA 282 1999 2131 2135
10. S. Woloshin, and L.M. Schwartz Distribution of C-reactive protein values in the United States N Engl J Med 352 2005 1611 1613
11. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
12. M. Cioffi, K. Esposito, M. Vietri, P. Gazzerro, A. D'Auria, and I. Ardovino Cytokine pattern in postmenopause Maturitas 41 2002 187 192
13. C.K. Sites, M.J. Toth, M. Cushman, G.D. L'Hommedieu, A. Tchermof, and R.P. Tracy Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal Fertil Steril 77 2002 128 135
14. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2002 836 843
15. J.K. Pai, T. Pischon, J. Ma, J.E. Manson, S.E. Hankinson, and K. Joshipura Inflammatory markers and the risk of coronary heart disease in men and women N Engl J Med 351 2004 2599 2610
16. K.K. Koh, W.H. Schenke, M. Waclawiw, G. Csako, and R.O. Cannon III Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women Circulation 105 2002 1531 1533
17. M. Cushman, C. Legault, E. Barrett-Connor, M.L. Stefanick, C. Kessler, and H.L. Judd Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study Circulation 100 1999 717 722
18. S. Vehkavaara, A. Silveira, T. Hakala-Ala-Pietila, A. Virkamaki, O. Hovatta, and A. Hamsten Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women Thromb Haemost 85 2001 619 625
19. D.M. Herrington, K.B. Brosnihan, B.E. Pusser, E.W. Seely, P.M. Ridker, and N. Rifai Differential effects of estrogen and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women J Clin Endocrinol Metab 86 2001 4216 4222
20. M. Cushman, E.N. Meilahn, B.M. Psaty, L.H. Kuller, A.S. Dobs, and R.P. Tracy Hormone replacement therapy, inflammation, and hemostasis in elderly women Arterioscler Thromb Vasc Biol 19 1999 893 899
21. B.W. Walsh, D.A. Cox, A. Sashegyi, R.A. Dean, R.P. Tracy, and P.W. Anderson Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women Am J Cardiol 88 2001 825 828
22. A. Silvestri, O. Gebara, C. Vitale, M. Wajngarten, F. Leonardo, and J.A. Ramires Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response Circulation 107 2003 3165 3169
23. A. Decensi, U. Omodei, C. Robertson, B. Bonanni, A. Guerrieri-Gonzaga, and F. Ramazzotto Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women Circulation 106 2002 1224 1228
24. N. Sattar, M. Perera, M. Small, and M.A. Lumsden Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes Lancet 354 1999 487 488
25. M.G. Modena, F. Bursi, G. Fantini, A. Cagnacci, A. Carbonieri, and A. Fortuna Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen Am J Med 113 2002 331 334
26. C.A. Blum, B. Müller, P. Huber, M. Kraenzlin, C. Schindler, and C. De Geyter Low-grade inflammation and estrimates of insulin resistance during the menstrual cycle in lean and overweight women J Clin Endocrinol Metab 90 2005 3230 3235
27. A. Wakatsuki, Y. Okatani, N. Ikenoue, and T. Fukaya Effect of medroxyprogesterone acetat on vascular inflammatory markers in postmenopausal women receiving estrogen Circulation 105 2002 1436 1439
28. S. Lamon-Fava, B. Posfai, and E.J. Schaefer Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women Am J Cardiol 91 2003 252 254
29. K.K. Koh, M.S. Shin, I. Sakuma, J.Y. Ahn, D.K. Jin, and H.S. Kim Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women Arterioscler Thromb Vasc Biol 24 2004 1516 1521
30. S. Verma, and E.T.H. Yeh C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation Am J Physiol Regul Integr Comp Physiol 285 2003 1253 1256
31. C.T. Esmon Crosstalk between inflammation and thrombosis Maturitas 47 2004 305 314
32. A.D. Pradhan, J.E. Manson, J.E. Roussouw, D.S. Siscovick, C.P. Mouton, and N. Rifai Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative observational study JAMA 288 2002 980 987
33. M.A. Albert, R.J. Glynn, and P.M. Ridker Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score Circulation 108 2003 161 165
34. T. Caulin-Glaser, C.A. Watson, R. Pardi, and J.R. Bender Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression J Clin Invest 98 1996 36 42
35. A.P. Miller, W. Feng, D. Xing, N.M. Weathington, J.E. Blalock, and Y.F. Chen Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries Circulation 110 2004 1664 1669
36. S. Pervin, R. Singh, M.E. Rosenfeld, M. Navab, G. Chaudhuri, and L. Nathan Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis Arterioscler Thromb Vasc Biol 18 1998 1575 1582
37. S. Srivastava, M.N. Weitzmann, S. Cenci, F.P. Ross, S. Adler, and R. Pacifici Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD J Clin Invest 104 1999 503 513
38. D.A. Sukovich, K. Kauser, F.D. Shirley, V. DelVecchio, M. Halks-Miller, and G.M. Rubanyi Expression of interleukin-6 in atherosclerotic lesions of male apoE-knockout mice Arterioscler Thromb Vasc Biol 18 1998 1498 1505
39. K.K. Koh, M.N. Bui, R. Mincemoyer, and R.O. Cannon III Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women Am J Cardiol 80 1997 1505 1507
40. K.K. Koh, A. Blum, L. Hathaway, R. Mincemoyer, G. Csako, and M.A. Waclawiw Vascular effects of estrogen and vitamin E therapies in postmenopausal women Circulation 100 1999 1851 1857
41. K.K. Koh, D.K. Jin, S.H. Yang, S.K. Lee, H.Y. Hwang, and M.H. Kang Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women Circulation 103 2001 1961 1966
42. S. Stork, K. Baumann, C. von Schacky, and P. Angerer The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women Cardiovasc Res 53 2002 642 649
43. K.K. Koh, J.W. Son, D.K. Jin, J.Y. Ahn, S.-.K. Lee, and H.Y. Hwang Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels Int J Cardiol 81 2001 43 50
44. K.K. Koh, J.Y. Ahn, D.K. Jin, B.K. Yoon, H.S. Kim, and D.S. Kim Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women Arterioscler Thromb Vasc Biol 22 2002 1459 1464
45. T.W. Meade, J.D. Imerson, A.P. Haines, Y. Stirling, and S.G. Thompson Menopausal status and haemostatic variable Lancet 1 1983 22 24
46. A.R. Folsom, K.K. Wu, C.E. Davis, M.G. Conlan, P.D. Sorlie, and M. Szklo Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors Atherosclerosis 91 1991 191 205
47. O.C.E. Gebara, M.A. Mittleman, P. Sutherland, I. Lipinska, T. Matheney, and P. Xu Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study Circulation 91 1995 1952 1958
48. S. Pinto, C. Rostagno, M. Coppo, R. Paniccia, D. Prisco, and V. Bruni No signs of increased thrombin generation in menopause Thromb Res 58 1990 645 651
49. The writing group for the PEPI trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial JAMA 273 1995 199 208
50. K.K. Koh, R. Mincemoyer, M.N. Bui, G. Csako, F. Pucino, and V. Guetta Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women N Engl J Med 336 1997 683 690
51. F. Blei, E.L. Wilson, P. Mignatti, and D.B. Rifkin Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis J Cell Physiol 155 1993 568 578
52. A. Takada, Y. Takada, and T. Urano The physiological aspects of fibrinolysis Thromb Res 76 1994 1 31
53. P.-.Y. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial Arterioscler Thromb Vasc Biol 17 1997 3071 3078
54. M.S. Post, M.J. van der Mooren, W.M. van Baal, M.A. Blankenstein, H.M. Merkus, and M.V. Kroeks Effects of low-dose and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study Am J Obstet Gynecol 189 2003 1221 1227
55. R.A. Lobo, J.H. Pickar, R.A. Wild, B. Walsh, and E. Hirvonen Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women Obstet Gynecol 84 1994 987 995
56. Y.G. Caine, K.A. Bauer, S. Barzegar, H. ten Cate, F.M. Sacks, and B.W. Walsh Coagulation activation following estrogen administration to postmenopausal women Thromb Haemost 68 1992 392 395
57. H. Jick, L.E. Derby, M.W. Myers, C. Vasilakis, and K.M. Newton Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Lancet 348 1996 981 983
58. N.L. Smith, S.R. Heckbert, R.N. Lemaitre, A.P. Reiner, T. Lumley, and N.S. Weiss Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis JAMA 292 2004 1581 1587
59. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941
60. U.H. Winkler Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings Fibrinolysis 6 S3 1992 5 10
61. K.K. Koh, M.K. Horne III, G. Csako, M. Waclawiw, and R.O. Cannon III Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women Am J Cardiol 83 1999 466 469
62. H.J. Teede, B.P. McGrath, J.J. Smolich, E. Malan, D. Kotsopoulos, and Y.L. Liang Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis Arterioscler Thromb Vasc Biol 20 2000 1404 1409
63. K.K. Koh, J.Y. Ahn, D.S. Kim, S.H. Han, M.S. Shin, and W.S. Ryu Effect of hormone replacement therapy on tissue factor activity, C-reactive protein, and the tissue factor pathway inhibitor Am J Cardiol 91 2003 371 373
64. E.J. Weiss, P.F. Bray, M. Tayback, S.P. Schulman, T.S. Kickler, and L.C. Becker A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis N Engl J Med 334 1996 1090 1094
65. D.T. Eitzman, R.J. Westrick, Y. Shen, P.F. Bodary, S. Gu, and S.L. Manning Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice Circulation 111 2005 1822 1825
66. C.J. Glueck, P. Wang, R.N. Fontaine, T. Tracy, L. Sieve-Smith, and J.E. Lang Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the Factor V Leiden mutation (resistance to activated protein C) Am J Cardiol 84 1999 549 554
67. D.M. Herrington, E. Vittinghoff, T.D. Howard, D.A. Major, J. Owen, and D.M. Reboussin Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease Arterioscler Thromb Vasc Biol 22 2002 1012 1017
68. K.K. Koh, J.Y. Ahn, D.K. Jin, B.K. Yoon, H.S. Kim, and D.S. Kim Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women Arterioscler Thromb Vasc Biol 23 2003 1889 1894
69. K.K. Koh, S.H. Han, M.-.S. Shin, J.Y. Ahn, Y. Lee, and E.K. Shin Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, crossover study Eur Heart J 26 2005 1362 1368
70. U.H. Winkler, R. Altkemper, B. Kwee, F.A. Helmond, and H.J. Coelingh Bennink Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study Fertil Steril 74 2000 10 19
71. T. Simoncini, and A.R. Genazzani Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells Mol Cell Endocrinol 162 2000 87 94
72. M.E. Mendelsohn, and R.H. Karas The time has come to stop letting the HERS tale wag the dogma Circulation 104 2001 2256 2259
73. K.K. Koh, and I. Sakuma Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol 24 2004 1171 1179
74. M.E. Mendelsohn, and R.H. Karas Molecular and cellular basis of cardiovascular gender differences Science 308 2005 1583 1587
75. A.P. Miller, D. Xing, W. Feng, M. Fintel, Y.-.F. Chen, and S. Oparil Aged rats lose estrogen-induced vasoprotective and anti-inflammatory effects in injured arteries Circulation 110 Supple III 2004 III-315
76. K.K. Koh, M.H. Kang, D.K. Jin, S.K. Lee, J.Y. Ahn, and H.Y. Hwang Vascular effects of estrogen in type II diabetic postmenopausal women J Am Coll Cardiol 38 2001 1409 1415
77. L.P. Mayer, C.A. Dyer, R.L. Eastgard, P.B. Hoyer, and C.L. Banka Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause Arterioscler Thromb Vasc Biol 25 2005 1910 1916
78. J.E. Manson, J. Hsia, K.C. Johnson, J.E. Rossouw, A.R. Assaf, and N.L. Lasser Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
79. R.A. Lobo Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials Arch Intern Med 164 2004 482 484
80. A. Simon, E. Oger, D. Wahl, J. Conrad, G. Plu-Bureau, and G. Meyer Indicators of lifetime endogenous exposure are associated with increased risk of venous thromboembolism Circulation 112 Supple II 2005 II-815
81. A. Ferrara, C.P. Quesenberry, A.J. Karter, C.W. Njoroge, A.S. Jacobson, and J.V. Selby Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998 Circulation 107 2003 43 48
82. S.M. Harman, E.A. Brinton, M. Cedars, R. Lobo, J.E. Manson, and G.R. Merriam KEEPS: The Kronos Early Estrogen Prevention Study Climacteric 8 2005 3 12